Dossier assessment
Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V
Report documents
-
Extract of dossier assessment
Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V
-
Dossier assessment
Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V
Dossier assessment
First-line treatment of adult patients with squamous non-small cell lung cancer (NSCLC) with locally advanced NSCLC for whom surgical resection or platinum-based chemoradiation is not an option, or with metastatic NSCLC
- Patients with PD‑L1‑expression ≥ 50% and without treatable genetic alterations: added benefit not proven
- Patients with PD‑L1‑expression < 50% and without treatable genetic alterations: added benefit not proven
Project details
- Project no.
- A24-126
- Commission
- Commission awarded on 20.12.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-126_en
Connected Projects
-
Dossier assessment
Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (oesophageal carcinoma, advanced, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed